Non-profit research company Hope Biosciences Stem Cell Research Foundation (HBSCRF) reported on Monday the receipt of Food and Drug Administration (FDA) authorisation for a free Phase II clinical trial of stem cells in subjects with Parkinson's Disease.
The US FDA has approved the company's Phase II free clinical trial to assess the efficacy and safety of multiple intravenous infusions of allogeneic adipose-derived mesenchymal stem cells in improving daily living and quality of life in patients with Parkinson's Disease.
This 60-patient trial is the second FDA clinical trial authorisation in Parkinson's for the company, which already has a 24-patient double-blind placebo trial underway utilizing autologous adipose-derived mesenchymal stem cells. Participants can be male or female, between 45-80 years of age and must have been diagnosed with mild-to-moderate Parkinson's at least two years prior to commencement.
In conjunction with the approval, the company said it will become the first research organization in the US to conduct simultaneous trials examining effects of administering the patient's own cells (autologous) and donor cells (allogeneic) for Parkinson's Disease.
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study